Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089121 · ClinicalTrials.gov registry record · Phase 1
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
A Phase 1 study of Juvenile Dermatomyositis and ANCA-Associated Vasculitis (AAV), sponsored by Cartesian Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07089121: Recruiting Phase 1 study of Juvenile Dermatomyositis and ANCA-Associated Vasculitis (AAV), sponsored by Cartesian Therapeutics.
NCT07089121 is a Phase 1 study of Juvenile Dermatomyositis and ANCA-Associated Vasculitis (AAV) that is actively recruiting participants, run by Cartesian Therapeutics. The registered enrollment target is 50 participants, below the 1,885-participant average among 3 other Juvenile Dermatomyositis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07089121, a Phase 1 study of Juvenile Dermatomyositis and ANCA-Associated Vasculitis (AAV), is actively recruiting participants, sponsored by Cartesian Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Primary Outcome
The primary endpoint for Part-1 is the Maximum Tolerated Dose (MTD), defined as the Dose Level at which no more than 20% of the patients treated have shown Dose-Limiting Toxicity (DLT), i.e. at which 3 patients received all 6 weekly infusions without a DLT by Day 50; or 6 patients received 3 weekly infusions with no more than 1 patient having a DLT by Day 50. The primary endpoint for Part-2 is the type and frequency of treatment-related SAEs. This will be assessed on Days 22, 50 and Months 3,6,
Conditions Studied
Interventions
- DRUG Descartes-08
Study Locations (1)
Missouri
- H03 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT07089121 shows while recruiting
NCT07089121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,885-participant average among 3 other Juvenile Dermatomyositis trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Juvenile Dermatomyositis appearing as the primary indexed condition, and to 1 intervention - of which Descartes-08 is the first listed.
NCT07089121 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07089121 about?
NCT07089121 is a clinical study titled "Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders". Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
What is the current status of trial NCT07089121?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-01. Estimated completion is 2026-12.
What conditions does trial NCT07089121 study?
This clinical trial studies the following conditions: Juvenile Dermatomyositis, ANCA-Associated Vasculitis (AAV), Childhood-onset Systemic Lupus Erythematous, Juvenile Myasthenia Gravis.
What interventions are being tested in trial NCT07089121?
The interventions under investigation include: Descartes-08 (DRUG).
Who is sponsoring clinical trial NCT07089121?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07089121 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
RECRUITING
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Environmental Risk Factors for the Anti-synthetase Syndrome
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia